Radiation plus targeted drug shows promise for Hard-to-Treat cancers

NCT ID NCT06814496

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times

Summary

This study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive both treatments, and researchers will monitor side effects and tumor shrinkage. The goal is to find a new way to control these cancers when other treatments have stopped working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arizona Cancer Center at UMC North/University Medical Center

    RECRUITING

    Tucson, Arizona, 85719, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Washington Fred Hutchinson Cancer Center

    NOT_YET_RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.